Lower plasma soluble TWEAK concentration in patients with newly diagnosed hypertension

Clinical and Investigative Medicine

Volumn 35, Issue 1, 2012, Pages

  Karadurmus, Nuri ^a   Tapan, Serkan ^a   Cakar, Mustafa ^a   Naharci, Ilkin ^a   Celik, Turgay ^a   Tasci, Ilker ^a   Sayin, Selim ^a   Dogan, Tolga ^a   Turker, Turker ^a   Erbil, M Kemal ^a   Saglam, Kenan ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; TNFSF12 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; BLOOD; BODY MASS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HYPERTENSION; MALE;

ADULT; BIOLOGICAL MARKERS; BODY MASS INDEX; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; HYPERTENSION; MALE; TUMOR NECROSIS FACTORS;

EID: 84861303311     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Bautista LE. Inflammation, endothelial dysfunction, and the risk of high blood pressure: epidemiologic and biological evidence. Journal of Human Hypertension. 2003, 17, 4, 223-30
2. Cai H, Harrison D. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circulation Research. 2000, 87, 10, 840-4.
3. Chicheportiche Y, Bourdon PR, Xu H, et al. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. the Journal of Biological Chemistry. 1997, 272, 51, 32401-10
4. Maecker H, Varfolomeev E, Kischkel F, et al. TWEAK attenuates the transition from innate to adaptive immunity. Cell. 2005, 123, 5, 931-44
5. Saitoh T, Nakayama M, Nakano H, et al. TWEAK induces NFkappaB2 p100 processing and long lasting NF-kappaB activa-tion. the Journal of Biological Chemistry. 2003, 278, 38, 36005-12
6. Kralisch S, Ziegelmeier M, Bachmann A, et al. Serum levels of the atherosclerosis biomarker sTWEAK are decreased in type 2 diabetes and end-stage renal disease. Atherosclerosis. 2008, 199, 2, 440-4
7. Blanco-Colio LM, Martín-Ventura JL, Munoz-Garcia B, et al. Identification of Soluble tumor Necrosis Factor-Like Weak Inducer of Apoptosis (sTWEAK) as a Possible Biomarker of Subclinical Atherosclerosis. Arterioscler thromb Vasc Biol. 2007, 27, 4, 916-22
8. Yilmaz MI, Carrero JJ, Ortiz A, et al. Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease. Clinical journal of the American Society of Nephrology. 2009, 4, 11, 1716-23
9. Böger R, Vallance P, Cooke J. Asymmetric dimethylarginine (ADMA): a key regulator of nitric oxide synthase. Atherosclerosis. 2003, 4, 4, 1-3
10. Ito A, Tsao PS, Adimoolam S, et al. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Cell. 1999, 99, 24, 3092-5
11. Landim MBP, Casella Filho A, Chagas ACP. Asymmetric dimethylarginine (ADMA) and endothelial dysfunction: implications for atherogenesis. Clinics (Sao Paulo). 2009, 64, 5, 471-8
12. Schulz E, Gori T, Münzel T. Oxidative stress and endothelial dysfunction in hypertension. Hypertens Res. 2011, 34, 6, 665-73
13. Yilmaz MI, Sonmez A, Ortiz A, et al. Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes. Clinical journal of the American Society of Nephrology. 2011, 6, 4, 785-92
14. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative Ultracentrifuge. Clinical Chemistry. 1972, 18, 6, 499-502
15. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modi-fiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937-52.
16. Yilmaz M, Stenvinkel P, Sonmez A, et al. Vascular health, systemic inflammation and progressive reduction in kidney function; clinical determinants and impact on cardiovascular outcomes. Nephrol Dial Transplant. 2011;26(11):3537-43.
17. Tasli{dotless}pi{dotless}nar A, Yaman H, Yi{dotless}lmaz M, et al. the relationship between inflammation, endothelial dysfunction and proteinuria in patients with diabetic nephropathy. Scand J Clin Lab Invest. 2011, 71, 7, 606-12
18. Yilmaz MI, Sonmez A, Saglam M, et al. Hemoglobin is inversely related to flow-mediated dilatation in chronic kidney disease. Kidney International. 2009, 75, 12, 1316-21
19. Böger RH. the emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovascular Research. 2003;59(4):824-33.
20. Yi{dotless}lmaz M, Carrero JJ, Martín-Ventura JL, et al. Combined therapy with Renin-Angiotensin System and Calcium Channel Blockers in Type 2 Diabetic Hypertensive Patients with Proteinuria: Effects on Soluble TWEAK, PTX3, and Flow-Mediated Dilation. Clinical journal of the American Society of Nephrology. 2010, 5, 7, 1174-81
21. Celermajer DS. Endothelial dysfunction: does it matter? Is it reversible. Journal of the American College of Cardiology. 1997, 30, 2, 325-33
22. Furchgott R, Zawadzki J. the obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980, 288, 5789, 373-6.
23. Quyyumi AA. Endothelial function in health and disease: new insights into the genesis of cardiovascular disease. Am J Med. 1998, 105, 1A, 32-9.
24. Vane J, Anggård E, Botting R. Regulatory functions of the vascular endothelium. N Engl J Med. 1990, 323, 1, 27-36.
25. Ceravolo R, Maio R, Pujia A, et al. Pulse pressure and endothelial dysfunction in never-treated hypertensive patients. Journal of the American College of Cardiology. 2003, 41, 10, 1753-8
26. Päivä H, Laakso J, Laine H, et al. Plasma Asymmetric Dimethylarginine and Hyperemic Myocardial Blood Flow in Young Subjects With Borderline Hypertension or Familial Hypercholesterolemia. Journal of the American College of Cardiology. 2002, 40, 7, 1241-7
27. Melikian N, Wheatcroft SB, Ogah OS, et al. Endothelium and Nitric Oxide Asymmetric Dimethylarginine and Reduced Nitric Oxide Bioavailability in Young Black African Men. Hypertension. 2007, 49, 4, 873-7
28. Kielstein JT, Fliser D. The past, presence and future of ADMA in nephrology. Nephrol Ther. 2007, 3, 2, 47-54
29. Miyazaki H, Matsuoka H, Cooke J, et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation. 1999, 99, 9, 1141-6
30. Justo P, Sanz AB, Sanchez-Niño MD, et al. Cytokine cooperation in renal tubular cell injury: the role of TWEAK. Kidney International. 2006, 70, 10, 1750-8
31. Kielstein J, Bode-Böger S, Frölich J,et al. R. Relationship of asymmetric dimethylarginine to dialysis treatment and atherosclerotic disease. Kidney Int Suppl Review 2001 78, S9-13
32. Jelic-Ivanovic Z, Bujisic N, Spasic S, Bogavac-Stanojevic, N'Spasojevic-Kalimanovska V, Kotur-Stevuljevic J. Circulating sTWEAK improves the prediction of coronary artery disease. Clin Biochem. 2009, 42, 13-14, 1381-6.
33. Chorianopoulos E, Rosenberg M, Zugck C, et al. Decreased soluble TWEAK levels predict an adverse prognosis in patients with chronic stable heart failure. European Journal of Heart Failure. 2009, 11, 11, 1050-6
34. Moreno J, Muñoz-García B, Martín-Ventura J, et al. The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis. Atherosclerosis. 2009, 207, 1, 103-10
35. Axelsson J, Møller H, Witasp A, et al. Changes in fat mass correlate with changes in soluble sCD163, a marker of mature macrophages, in patients with CKD. Am J Kidney Dis. 2006, 48, 6, 16-25